

ABSTRACT OF THE DISCLOSURE

Provided herein are methods of reducing nephrotoxicity from at least one alpha particle-emitting daughter of actinium-225 during radioimmunotherapeutic treatment for a pathophysiological condition, methods of improving radioimmunotherapeutic treatment of cancer and methods of increasing the therapeutic index of an actinium-225 radioimmunoconjugate during treatment of a pathophysiological condition. Adjuvants effective for preventing accumulation of ^{225}Ac daughters within the kidneys are administered during treatment with an actinium-225 radioimmunoconjugate to reduce nephrotoxicity. Examples of adjuvants are chelators, diuretics and/or competitive metal blockers.